Recurrence of Cancer-associated Venous Thromboembolism between 2009 and 2013: A Nationwide Korean Study

Hwang, Hun-Gyu; Lee, Ju Hyun; Hong, Junshik; Kim, Sang-A; Kim, Yang Ki; Kim, Myungshin; Bang, Soo‐Mee

doi:10.14345/ceth.21003

Cited by 5 publications

(3 citation statements)

References 32 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2 15 Direct oral anticoagulants (DOAC) has been covered by the Korean insurance service since January 2013 and began to replace previously established anticoagulants. 16 DOACs have major pharmacologic advantages over warfarin, including rapid onset/off set of action, few drug interactions, predictable pharmacokinetics and no need for INR monitoring. Increased awareness of VTE among clinicians and easy access to standard imaging methods for diagnosis has created a virtuous cycle of further diagnosis and optimal treatment.…”

Section: Introductionmentioning

confidence: 99%

Incidence of Venous Thromboembolism: The 3^rdKorean Nationwide Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background The incidence of venous thromboembolism (VTE) has gradually increased in the Korean population. This study aimed to evaluate the annual age- and sex-adjusted incidence rates (ASR) of VTE and anticoagulation trends between 2014 and 2018. Methods Using the Korean Health Insurance Review and Assessment Service database, we retrospectively identified VTE patients between 2014 and 2018 using both diagnostic and medication anticoagulant codes assigned within 6 months of the initial index event. Anticoagulant patterns were classified as follows: direct oral anticoagulants (DOAC), parenteral anticoagulants, warfarin, and mixed anticoagulation regimens. Results We identified 95,205 patients with VTE (female, 56.8%). The ASR for VTE per 100,000 person-years increased from 32.8 in 2014 to 53.7 cases in 2018 (relative risk of 1.63; 95% confidence interval, 1.6–1.67). The VTE incidence rates were 25 times higher in the ≥ 80 group than in the 30s group. VTE occurred 1.29 times more often in women than in men. The proportion of DOAC prescriptions increased from 40.5% to 72.8%, whereas warfarin prescriptions decreased from 27% to 5.6% in 2014 and 2018. Conclusion In Korea, the ASRs of VTE continued to increase since 2014, but the rate of increase slowed in 2018. The VTE occurred more often in the elderly and in women. Five years after the introduction of DOACs in 2013, they accounted for 73% of all anticoagulants used to treat VTE.

show abstract

Section: Introductionmentioning

confidence: 99%

Incidence of Venous Thromboembolism: The 3^rdKorean Nationwide Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Despite potential ascertainment bias, the 12-month VTE recurrence rate was reported to be 6.7%-15.3% in 6 large cohort studies (Table 5). 5,22,[35][36][37][38] All except one of the studies were performed before the DOAC era. Reliable longer-term VTE recurrence data beyond 1-year are lacking.…”

Section: Recurrence Risk After Cancer-associated Thrombosis Diagnosismentioning

confidence: 99%

Trends and updates on the epidemiology of cancer-associated thrombosis: a systematic review

Li,

Zhou

2024

Bleed Thromb Vascul Biol

View full text Add to dashboard Cite

For cancer patients, cancer-associated thrombosis (CAT) is a serious complication. An updated epidemiology of CAT over the last ten years is summarized in this review. A comprehensive analysis of pertinent population cohort research released between 2011 and 2024 was carried out. In patients with unselected cancers, the 12-month incidence of CAT is roughly 3-5% (9-fold increase vs to the matched non-cancer population); however, in patients with advanced cancers requiring systemic therapy, the risk rises to 6-8% (20-fold increase vs. to the matched non-cancer population). Anticoagulation use and adherence have improved, but the risk of recurrence is still high, at 5-8% at 6 months and 7-15% at 12 months. The type, stage, and treatment of cancer, a history of venous thromboembolism (VTE), prolonged hospitalization or immobilization, and obesity are significant clinical predictors of the development of CAT. The modified Vienna-CATS and EHR-CAT have the best performance (area under the curve 0.68-0.71) among the clinical risk prediction scores for CAT using the original Khorana score backbone that has been externally validated. However, additional research is required to guarantee appropriate implementation and utilization of these models. Even with contemporary antineoplastic treatments, CAT is still a major complication for cancer patients. We encourage interdisciplinary partnerships among hematologists, data scientists, epidemiologists, and oncologists to guarantee the integration of customized VTE risk evaluation into standard oncologic treatment.

show abstract

“…This disparity may be due to genetic differences in thrombophilia between Asian and Caucasian people [ 10 ]. Other than inherited conditions, cancer is the most common cause of VTE, and is responsible for 15–33% of VTE in Asian patients [ 11 , 12 ]. However, few studies have described the risk factors of VTE in Asian patients with breast cancer.…”

Section: Introductionmentioning

confidence: 99%

The Risk of Venous Thromboembolism in Korean Patients with Breast Cancer: A Single-Center Experience

Park

Ahn

Kwon

et al. 2023

Cancers

View full text Add to dashboard Cite

The relationship between cancer and venous thromboembolism (VTE) has long been described. The risk of VTE in Asian patients with breast cancer remains largely unknown. This study described the incidence and risk factors of VTE in Korean patients with breast cancer. Data were collected from a retrospective database of patients who underwent breast cancer surgery between 2011 and 2020 at a single institution. The Cox proportional-hazards model was used to identify factors associated with VTE occurrences. Among the 2246 patients with breast cancer, 48 (2.1%) developed VTE during a median follow-up period of 53 months. The average incidence of VTE was 459 per 100,000 person-years. Age ≥ 60 years, male sex, chronic kidney disease, reconstructive procedures, and stage II or higher were independent predictive factors for VTE. VTE was associated with poor disease-free survival (hazard ratio (HR), 6.140; 95% confidence interval (CI), 3.480–10.835), and overall survival (HR, 8.842; 95% CI 4.386–17.824). Most VTE events were manageable with anticoagulation; three (6.3%) patients died of VTE, despite intensive care. The incidence of VTE was significantly elevated in Korean patients with breast cancer. Since VTE has a negative effect on oncologic outcomes of breast cancer, clinicians should manage its risk throughout their lifetime.

show abstract

Recurrence of Cancer-associated Venous Thromboembolism between 2009 and 2013: A Nationwide Korean Study

Cited by 5 publications

References 32 publications

Incidence of Venous Thromboembolism: The 3^rdKorean Nationwide Study

Incidence of Venous Thromboembolism: The 3^rdKorean Nationwide Study

Trends and updates on the epidemiology of cancer-associated thrombosis: a systematic review

The Risk of Venous Thromboembolism in Korean Patients with Breast Cancer: A Single-Center Experience

Contact Info

Product

Resources

About

Recurrence of Cancer-associated Venous Thromboembolism between 2009 and 2013: A Nationwide Korean Study

Cited by 5 publications

References 32 publications

Incidence of Venous Thromboembolism: The 3rdKorean Nationwide Study

Incidence of Venous Thromboembolism: The 3rdKorean Nationwide Study

Trends and updates on the epidemiology of cancer-associated thrombosis: a systematic review

The Risk of Venous Thromboembolism in Korean Patients with Breast Cancer: A Single-Center Experience

Contact Info

Product

Resources

About

Incidence of Venous Thromboembolism: The 3^rdKorean Nationwide Study

Incidence of Venous Thromboembolism: The 3^rdKorean Nationwide Study